SenesTech stock adds Grove channel as Q2 revenue hits USD 770,000

SenesTech stock is tied to a new consumer distribution channel after the company announced on September 23, 2026, that its Evolve rodent birth control products will soon be available through Grove Collaborative. The announcement adds a measurable commercial milestone to a company that reported USD 770,000 in second-quarter 2026 revenue and a GAAP loss of USD 1.83 million.

Grove adds a consumer channel

According to PR Newswire on September 23, 2026, Evolve products are expected to reach Grove's online marketplace soon. SenesTech said the partnership is intended to expand access to consumers seeking products with naturally derived ingredients and sustainability credentials.

The channel matters because SenesTech serves both consumer and professional markets, while Grove already operates as a sustainability-focused marketplace. The release also identifies Evolve and ContraPest as fertility-control products designed to reduce rodent populations by targeting reproduction, rather than relying solely on traditional rodenticides.

Revenue rises from the first quarter

Second-quarter revenue of USD 770,000 was higher than the USD 493,000 reported for the first quarter of 2026, a 56.19 percent increase. The company still posted a second-quarter net loss of USD 1.83 million, compared with a USD 2.06 million loss in the first quarter.

GAAP diluted EPS was minus USD 0.35 in Q2 2026, versus a consensus estimate of minus USD 0.37, according to Yahoo Finance. The USD 0.02 beat narrows the earnings gap, but the negative net income keeps operating execution central to the stock story.

Nasdaq value remains modest

On Nasdaq, SNES was trading at USD 0.65 on September 29, 2026, at 2:11 p.m. ET. Its market capitalization was USD 3.4 million, while the 52-week range stood at USD 0.62 to USD 4.61 on the same date.

Zacks reported on September 9, 2026, that its analyst raised the 2026 revenue target by 20 percent and maintained a USD 3.50 price target. That target is materially above the September 29 Nasdaq price, leaving revenue conversion through new channels as the key test for the commercial strategy.